AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16329022 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal EGD (XP-N)
Number of subjects: 450
Study 16329022 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral EGD with small-caliber endoscope (XP-O)
Number of subjects: 450
Study 16329022 — intervention group
Group type: COMPARATOR
Intervention: Transoral EGD with conventional endoscope (XQ)
Number of subjects: 450
Study 11917284 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (500 mg intravenously, twice weekly before chemoradiation)
Number of subjects: 60
Study 11917284 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiation without amifostine
Number of subjects: 60
Study 7942476 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine echocardiography
Number of subjects: 0
Study 7942476 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting thallium‐201 scintigraphy
Number of subjects: 0
Study 3236328 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 180 mg once daily
Number of subjects: 8
Study 3236328 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 90 mg twice daily
Number of subjects: 8
Study 3236328 — intervention group
Group type: COMPARATOR
Intervention: Wash-out period
Number of subjects: 8
Study 31880586 — intervention group
Group type: EXPERIMENTAL
Intervention: Arteriovenous fistula (AVF) usage for more than 8 months
Number of subjects: 705
Study 31880586 — intervention group
Group type: EXPERIMENTAL
Intervention: Central venous catheter (CVC) usage for less than 4.2 months
Number of subjects: 705
Study 31880586 — intervention group
Group type: COMPARATOR
Intervention: Less than 2.8 months of AVF usage
Number of subjects: 705
Study 31880586 — intervention group
Group type: COMPARATOR
Intervention: More than 9.2 months of CVC usage
Number of subjects: 705
Study 29231317 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 61
Study 29231317 — intervention group
Group type: COMPARATOR
Intervention: Estazolam
Number of subjects: 61
Study 26574300 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentiated ZPT shampoo
Number of subjects: 0
Study 22942402 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural education intervention
Number of subjects: 110
Study 22942402 — intervention group
Group type: COMPARATOR
Intervention: Control group (information leaflet)
Number of subjects: 110
Study 21485668 — intervention group
Group type: EXPERIMENTAL
Intervention: PercuTwist
Number of subjects: 87
Study 21485668 — intervention group
Group type: COMPARATOR
Intervention: Griggs' forceps dilational tracheostomy
Number of subjects: 87
Study 21485668 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 87
Study 19909590 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimicifuga racemosa (phytoestrogen)
Number of subjects: 134
Study 19909590 — intervention group
Group type: COMPARATOR
Intervention: ethinyl oestradiol
Number of subjects: 134
Study 16169093 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal mometasone furoate monohydrate 100 mcg/day
Number of subjects: 122
Study 16169093 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 122
Study 15202297 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors, beta-blockers, and aldosterone antagonists (combined therapy)
Number of subjects: 0
Study 15202297 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors, beta-blockers, and aldosterone antagonists (individual drugs)
Number of subjects: 0
Study 11388000 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha 2-macroglobulin (alpha 2M) and transferrin (Tf) concentrations
Number of subjects: 13
Study 11388000 — intervention group
Group type: EXPERIMENTAL
Intervention: Microheterogeneity of alpha 2M and Tf
Number of subjects: 13
Study 9241006 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepirone (10 to 45 mg daily)
Number of subjects: 198
Study 9241006 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (19.5 +/- 12.5 mg/day)
Number of subjects: 198
Study 9241006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 9241006 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepirone
Number of subjects: 198
Study 9241006 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 198
Study 8309606 — intervention group
Group type: EXPERIMENTAL
Intervention: e.v. immunoglobulins (300 mg/kg per day, for three days)
Number of subjects: 89
Study 8309606 — intervention group
Group type: EXPERIMENTAL
Intervention: e.v. immunoglobulins associated with routine antibiotic prophylaxis
Number of subjects: 89
Study 8309606 — intervention group
Group type: COMPARATOR
Intervention: Routine antibiotic prophylaxis
Number of subjects: 89
Study 2894903 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: tubocurarine (DTC) 3 mg + succinylcholine 1.5 mg.kg‐1
Number of subjects: 0
Study 2894903 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: atracurium 0.05 mg.kg‐1 + 0.35 mg.kg‐1
Number of subjects: 0
Study 2894903 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: vecuronium, 0.01 mg.kg‐1 + 0.07 mg.kg‐1
Number of subjects: 0
Study 2894903 — intervention group
Group type: COMPARATOR
Intervention: Group D: no relaxant
Number of subjects: 0
Study 2894903 — intervention group
Group type: EXPERIMENTAL
Intervention: Group E: DTC 0.05 mg.kg‐1 + vecuronium 0.07 mg.kg‐1
Number of subjects: 0
Study 2894903 — intervention group
Group type: EXPERIMENTAL
Intervention: Group F: vecuronium 0.01 mg.kg‐1 + vecuronium 0.12 mg.kg‐1
Number of subjects: 0
Study 2894903 — intervention group
Group type: EXPERIMENTAL
Intervention: Group G: DTC 3 mg + succinylcholine 1.5 mg.kg‐1
Number of subjects: 0
Study 2894903 — intervention group
Group type: EXPERIMENTAL
Intervention: Group H: vecuronium 0.01 mg.kg‐1 + 0.09 mg.kg‐1
Number of subjects: 0
Study 2894903 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I: vecuronium 0.1 mg.kg‐1 as a single bolus
Number of subjects: 0
Study 30838799 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative antibiotics (AB group)
Number of subjects: 447
Study 30838799 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics (noAB group)
Number of subjects: 447
Study 29038203 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP plus Weight Loss
Number of subjects: 139
Study 29038203 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss
Number of subjects: 139
Study 29038203 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 139
Study 26133933 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS (Near-Infrared Spectroscopy)
Number of subjects: 79
Study 26133933 — intervention group
Group type: COMPARATOR
Intervention: No NIRS (Control)
Number of subjects: 79
Study 21787375 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated-low group
Number of subjects: 114
Study 21787375 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Hispanic group
Number of subjects: 114
Study 22626945 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (0.5 mg, increased to a maximum of 2 mg daily)
Number of subjects: 38
Study 22626945 — intervention group
Group type: COMPARATOR
Intervention: Ginkgo biloba (40 mg, increased to a maximum of 160 mg daily)
Number of subjects: 38
Study 19386096 — intervention group
Group type: EXPERIMENTAL
Intervention: XELIRI (irinotecan 250 mg/m² on day one, capecitabine 1000 mg/m² twice daily from day 2-15, every 21 days)
Number of subjects: 87
Study 19386096 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI (irinotecan 180 mg/m², 5-FU 400 mg/m², LV 200 mg/m², 5-FU 2400 mg/m² (46-h infusion) on day one, every 14 days)
Number of subjects: 87
Study 19386096 — intervention group
Group type: EXPERIMENTAL
Intervention: XELIRI
Number of subjects: 87
Study 19386096 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 87
Study 17879083 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerosing polidocanol injections (Group A)
Number of subjects: 20
Study 17879083 — intervention group
Group type: COMPARATOR
Intervention: Open surgical revision (Group B)
Number of subjects: 20
Study 14716731 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-modifying therapies
Number of subjects: 0
Study 14716731 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate markers (brain imaging)
Number of subjects: 0
Study 11552906 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide infusion
Number of subjects: 19
Study 11552906 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 19
Study 9559415 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline loading (250 ml of normal saline) with ACE inhibitor (delapril) after 5 days
Number of subjects: 10
Study 9559415 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline loading (250 ml of normal saline) without ACE inhibitor
Number of subjects: 10
Study 9559415 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 control subjects)
Number of subjects: 10
Study 9559415 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor (delapril)
Number of subjects: 10
Study 7513981 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary myelin basic protein-like material (MBPLM) in MS patients
Number of subjects: 166
Study 7513981 — intervention group
Group type: COMPARATOR
Intervention: Urinary MBPLM in MS patients
Number of subjects: 166
Study 7513981 — intervention group
Group type: COMPARATOR
Intervention: Treatment with glucocorticoids and immunosuppressants
Number of subjects: 166
Study 7513981 — intervention group
Group type: COMPARATOR
Intervention: Urinary MBPLM in patients with cranial magnetic resonance imaging
Number of subjects: 166
Study 7513981 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary MBPLM
Number of subjects: 166
Study 3299182 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 supplementation (150 mg daily)
Number of subjects: 55
Study 3299182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 30700145 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/AIDS media exposure
Number of subjects: 500
Study 30700145 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/AIDS knowledge
Number of subjects: 500
Study 30700145 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/AIDS attitude
Number of subjects: 500
Study 28334958 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help smoking relapse prevention intervention using the 'Forever Free' self-help booklets.
Number of subjects: 43
Study 28599953 — intervention group
Group type: EXPERIMENTAL
Intervention: Nap group
Number of subjects: 28
Study 28599953 — intervention group
Group type: COMPARATOR
Intervention: No Nap group
Number of subjects: 28
Study 25817527 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarettes
Number of subjects: 0
Study 25817527 — intervention group
Group type: COMPARATOR
Intervention: Active and passive controls
Number of subjects: 0
Study 24283110 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg (n=98)
Number of subjects: 192
Study 24283110 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg (n=94)
Number of subjects: 192
Study 24283110 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast agent administered
Number of subjects: 192
Study 24283110 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction
Number of subjects: 192
Study 21275437 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel therapy (600 mg loading dose and 75 mg/day maintenance dose) plus aspirin (300 mg/day)
Number of subjects: 149
Study 21275437 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients aged <75 years)
Number of subjects: 149
Study 17952589 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene (60 mg PO daily)
Number of subjects: 11
Study 17952589 — intervention group
Group type: COMPARATOR
Intervention: Exemestane (25 mg PO daily)
Number of subjects: 11
Study 17952589 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Raloxifene 60 mg PO daily + Exemestane 25 mg PO daily)
Number of subjects: 11
Study 16317581 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 71
Study 16317581 — intervention group
Group type: EXPERIMENTAL
Intervention: High vegetable-fruit diet
Number of subjects: 71
Study 16317581 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing plasma levels of lutein
Number of subjects: 71
Study 16317581 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing plasma levels of alpha-carotene
Number of subjects: 71
Study 14650558 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal barrier precautions (gloves, gowns, masks, hats, facial shields, glasses)
Number of subjects: 0
Study 14650558 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface disinfectants
Number of subjects: 0
Study 14650558 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-op 0.12% chlorhexidine mouth rinses
Number of subjects: 0
Study 14650558 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume evacuation
Number of subjects: 0
Study 14650558 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioral skin scrubs
Number of subjects: 0
Study 14650558 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber dam isolation, hand excavation and bond technique, high-speed air turbine and electric 'high' speed handpiece
Number of subjects: 0
Study 11155450 — intervention group
Group type: EXPERIMENTAL
Intervention: Phospholax solution (one dose in the evening two days before the examination and four doses the day before, two in the afternoon and two in the evening, followed by abundant hydration)
Number of subjects: 80
Study 11155450 — intervention group
Group type: COMPARATOR
Intervention: Traditional method (residue‐free diet for three days, sennoside-based laxative the morning before, magnesium sulphate in the afternoon)
Number of subjects: 80
Study 8973005 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient supplemented preterm formula
Number of subjects: 926
Study 8973005 — intervention group
Group type: COMPARATOR
Intervention: Standard formula milk
Number of subjects: 926
Study 8973005 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 926
Study 1289019 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime insulin (BTI)
Number of subjects: 9
Study 1289019 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning insulin (MI)
Number of subjects: 9
Study 3881323 — intervention group
Group type: EXPERIMENTAL
Intervention: d-penicillamine 1200 mg daily
Number of subjects: 189
Study 3881323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 3881323 — intervention group
Group type: EXPERIMENTAL
Intervention: d-penicillamine
Number of subjects: 189
Study 30759235 — intervention group
Group type: EXPERIMENTAL
Intervention: Sour cream
Number of subjects: 47
Study 30759235 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheese
Number of subjects: 47
Study 29143707 — intervention group
Group type: EXPERIMENTAL
Intervention: UltraRice®Original
Number of subjects: 1796
Study 29143707 — intervention group
Group type: EXPERIMENTAL
Intervention: UltraRice®New
Number of subjects: 1796
Study 29143707 — intervention group
Group type: EXPERIMENTAL
Intervention: NutriRice®
Number of subjects: 1796
Study 29143707 — intervention group
Group type: COMPARATOR
Intervention: Normal rice
Number of subjects: 1796
Study 26479169 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding (within 6 hours post-surgery)
Number of subjects: 177
Study 26479169 — intervention group
Group type: COMPARATOR
Intervention: Late feeding (after 12 hours post-surgery)
Number of subjects: 177
Study 24891548 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention with systems of support for completion of colorectal cancer screening
Number of subjects: 4675
Study 24891548 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4675
Study 23171304 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery focused CBT (RfCBT)
Number of subjects: 0
Study 23171304 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 20047560 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 145 mg/day
Number of subjects: 15
Study 20047560 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 15
Study 18257348 — intervention group
Group type: EXPERIMENTAL
Intervention: Common acupuncture group (traditional acupoint selection method)
Number of subjects: 96
Study 18257348 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance yin-yang acupuncture group (combined acupoints on yin and yang channels)
Number of subjects: 96
Study 18257348 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine medicine and rehabilitation training only)
Number of subjects: 96
Study 15130637 — intervention group
Group type: EXPERIMENTAL
Intervention: New phacoemulsification technology
Number of subjects: 0
Study 15130637 — intervention group
Group type: COMPARATOR
Intervention: Previously published results for the same machines before the new technology
Number of subjects: 0
Study 11722858 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with extra guidelines for the teacher (38 pupils)
Number of subjects: 120
Study 11722858 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group without extra guidelines (48 pupils)
Number of subjects: 120
Study 11722858 — intervention group
Group type: EXPERIMENTAL
Intervention: Candid camera evaluation for intervention group with guidelines (38 pupils)
Number of subjects: 120
Study 11722858 — intervention group
Group type: EXPERIMENTAL
Intervention: Candid camera evaluation for intervention group without guidelines (48 pupils)
Number of subjects: 120
Study 11722858 — intervention group
Group type: COMPARATOR
Intervention: Control group (34 pupils)
Number of subjects: 120
Study 11722858 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge test scores for both intervention groups
Number of subjects: 120
Study 10051930 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (group P, n = 26)
Number of subjects: 52
Study 10051930 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (group S, n = 26)
Number of subjects: 52
Study 10051930 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (group S)
Number of subjects: 52
Study 10051930 — intervention group
Group type: COMPARATOR
Intervention: Propofol (group P)
Number of subjects: 52
Study 10051930 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (group S, n = 24)
Number of subjects: 52
Study 10051930 — intervention group
Group type: COMPARATOR
Intervention: Propofol (group P, n = 2-5)
Number of subjects: 52
Study 10051930 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (group S, n = 13)
Number of subjects: 52
Study 10051930 — intervention group
Group type: COMPARATOR
Intervention: Propofol (group P, n = 12)
Number of subjects: 52
Study 10051930 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory anaesthesia failure
Number of subjects: 52
Study 10051930 — intervention group
Group type: EXPERIMENTAL
Intervention: Reoperation needed
Number of subjects: 52
Study 7973477 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximoprofen 5 mg daily
Number of subjects: 285
Study 7973477 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximoprofen 10 mg daily
Number of subjects: 285
Study 7973477 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximoprofen 20 mg daily
Number of subjects: 285
Study 7973477 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximoprofen 30 mg daily
Number of subjects: 285
Study 7973477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 2586204 — intervention group
Group type: EXPERIMENTAL
Intervention: Xipamide 20 mg once a day for 16 weeks
Number of subjects: 24
Study 2586204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1100213 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha methyldopahydrazine in combination with L-dopa
Number of subjects: 25
Study 1100213 — intervention group
Group type: COMPARATOR
Intervention: Placebo with L-dopa
Number of subjects: 25
Study 31896491 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day for 3 months
Number of subjects: 30
Study 31896491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30926571 — intervention group
Group type: EXPERIMENTAL
Intervention: Philani home‐visiting condition (HVC)
Number of subjects: 0
Study 30926571 — intervention group
Group type: COMPARATOR
Intervention: Standard care condition (SC)
Number of subjects: 0
Study 29236049 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D₃ 200,000 IU followed by monthly 100,000 IU doses (n = 226)
Number of subjects: 442
Study 29236049 — intervention group
Group type: COMPARATOR
Intervention: Placebo monthly (n = 216)
Number of subjects: 442
Study 26003640 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem administered every 6 hours
Number of subjects: 25
Study 26003640 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem administered every 8 hours
Number of subjects: 25
Study 26003640 — intervention group
Group type: EXPERIMENTAL
Intervention: CVVH mode with actual dose of replacement fluid (31.63±1.48) mL×kg⁻¹×h⁻¹
Number of subjects: 25
Study 26003640 — intervention group
Group type: EXPERIMENTAL
Intervention: AN69 filter
Number of subjects: 25
Study 23078984 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Intervention (MBI-ld)
Number of subjects: 186
Study 23078984 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle education program (active control)
Number of subjects: 186
Study 21594660 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient pain therapy for 3 weeks
Number of subjects: 200
Study 18758373 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release omeprazole 40 mg
Number of subjects: 55
Study 18758373 — intervention group
Group type: COMPARATOR
Intervention: Delayed-release lansoprazole 30 mg
Number of subjects: 55
Study 18758373 — intervention group
Group type: COMPARATOR
Intervention: Delayed-release pantoprazole 40 mg
Number of subjects: 55
Study 16224141 — intervention group
Group type: EXPERIMENTAL
Intervention: Men aged 50-64 years
Number of subjects: 5670
Study 16224141 — intervention group
Group type: EXPERIMENTAL
Intervention: Women aged 20-49 years
Number of subjects: 5670
Study 16224141 — intervention group
Group type: EXPERIMENTAL
Intervention: Older population (both genders)
Number of subjects: 5670
Study 16224141 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger population (both genders)
Number of subjects: 5670
Study 11872684 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 19